Martha Carlson reflects on her 11 years with metastatic breast cancer and explores how resilience, purpose and the stories we tell ourselves shape the cancer experience.
A study found that sentinel lymph node biopsy rarely missed remaining cancer in patients with locally advanced breast cancer whose lymph nodes responded to chemotherapy before surgery.
The FDA has cleared TumorSight Risk, software that uses a patient's existing breast MRI, pathology and clinical information to estimate the chance that early HR-positive, HER2-negative breast cancer will come back within five and 10 years.
Twenty-four years after breast cancer, one survivor reflects on mammogram anxiety, the relief of clear results and the gratitude of living beyond cancer.